Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorCharite University, Berlin, Germany

About this trial

The Stroke-CORE cohort aims to provide a comprehensive and up-to-date understanding of stroke care in Germany. To achieve this, patients are followed along the entire continuum of care-from initial management before hospital admission, through acute treatment, rehabilitation, and follow-up care, to the prevention of recurrent strokes. Strokes occurring in childhood are also included in this cohort study.

In addition, the study seeks to establish effective structures for the early identification and inclusion of patients in clinical research (screening). In this context, structured screening processes are being implemented across all levels of care at participating sites within the Network University Medicine (NUM), a collaboration of German university hospitals. At the same time, the cohort serves as a platform within this network to systematically address open research questions in various areas of stroke care and to support the targeted planning and conduct of future clinical studies.

The study includes patients with ischemic stroke (caused by a blocked blood vessel) or intracerebral hemorrhage (bleeding within the brain). Participation takes place in different thematic modules, each focusing on specific aspects of the disease course and its management. These modules address, among other topics, acute hospital treatment, measures to prevent recurrent strokes (secondary prevention), possible complications, pre-hospital care, rehabilitation, follow-up care, and long-term outcomes such as physical recovery, independence in daily life, and cognitive functions including memory and concentration.

As part of the study, a range of data is collected. This includes sociodemographic information (such as age and living situation) as well as medical data, for example on prior conditions, diagnoses, treatments, and comorbidities. In addition, patients' health status is assessed at multiple time points in order to better understand the course of the disease. Depending on the level of participation, data collection may be complemented by the collection of biological samples, such as blood. These are obtained either during routine clinical procedures or through simple, minimally burdensome (non-invasive) methods.

The study is structured into several levels that differ in the scope and depth of data collection. The basic level includes essential information, while higher levels involve more detailed assessments. In addition, some levels include the collection of biological samples, and there are optional supplementary modules in which patients may participate voluntarily. This tiered approach allows participation to be flexibly adapted to the individual situation while contributing to a nuanced and comprehensive understanding of stroke care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of AIS or ICH; the AIS diagnosis may be diagnosed clinically or radiologically (i.e., focal neurological impairment of sudden onset, lasting more than 24 hours and of presumed vascular origin, or with proof of cerebral ischaemia corresponding to the clinical symptoms in neuroimaging); for ICH diagnosis requires clinical symptoms and radiological diagnosis of ICH

Hospital admission <24h after symptom onset

Age 18+ years for the basic Modules AIS and ICH; age <18 years for the basic Module paediatric stroke patients

Informed consent: Signed IC from patients capable of giving consent and understanding all content of the IC or IC of an appropriate patient representative or deferred consent, if patients are unable to consent themselves

Disqualifiers

In-hospital stroke

TIA

SAH

Stroke as a complication of a medical procedure

Trial population

Stroke patients with criteria defined in each individual Module (IS, ICH, peadiatric stroke) who are admitted to one of the participating university hospitals in Germany within 24 hours of symptom onset. General inclusion and exclusion criteria: * Fulfilment of all inclusion and no exclusion criteria for at least one Module * Signed IC from patients capable of giving consent and understanding all content of the IC or IC of an appropriate patient representative, if patients are unable to provide consent themselves.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

12,750 Participants
are grouped into 3 trial groups
Group A: Ischemic Stroke
Group B: Intracerebral Hemorrhage
Group C: Paediatric Stroke

Trial outcomes

Primary outcomes

1

adaptive research platform addressing various and for the 3 groups different research questions

Outcomes include disease severity, standard of care, complications, recurrent ischaemic or haemorrhagic stroke, burden and impact of disease and treatment on quality of life, functional outcome and survival at different time points. Since SN Stroke is an adaptive research platform addressing various research questions, additional outcomes and different determinants influencing these outcomes may be added in each module.

Time frame
Depending on the group, outcome measures will be collected through study completion, primarily at baseline, follow-up at 3 and/or 6 months, and annually, with an average follow-up period expected to be 1 year.

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Charite University, Berlin, Germany

Lead sponsor

Universitätsklinikum Hamburg-Eppendorf

Collaborator

University Hospital Schleswig-Holstein

Collaborator

Wuerzburg University Hospital

Collaborator

This trial is not recruiting at the moment. You can still explore other options: